{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:22:21Z","timestamp":1791274941079,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,7,29]],"date-time":"2013-07-29T00:00:00Z","timestamp":1375056000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2013,7,29]],"date-time":"2013-07-29T00:00:00Z","timestamp":1375056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Grant-in-Aid for Scientific Research","award":["24590619"],"award-info":[{"award-number":["24590619"]}]},{"name":"Grant-in-Aid for Scientific Research","award":["23590603"],"award-info":[{"award-number":["23590603"]}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Health Labour Sciences Research Grant","award":["201132052A"],"award-info":[{"award-number":["201132052A"]}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100014475","name":"Pfizer Health Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014475","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1111\/jcpt.12089","type":"journal-article","created":{"date-parts":[[2013,7,30]],"date-time":"2013-07-30T04:48:52Z","timestamp":1375159732000},"page":"468-475","source":"Crossref","is-referenced-by-count":23,"title":["Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan"],"prefix":"10.1155","volume":"38","author":[{"given":"R.","family":"Shimazawa","sequence":"first","affiliation":[{"name":"Center for Clinical and Translational Research; Kyushu University; Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics; Kagawa University Hospital; Kagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,7,29]]},"reference":[{"key":"10.1111\/jcpt.12089-BIB0001|jcpt12089-cit-0001","unstructured":"U.S. Food and Drug Administration Guidance for Industry: Pharmacogenomic Data Submissions 2005 http:\/\/www.fda.gov\/downloads\/Regula-toryInformation\/Guidances\/ucm126957.pdf"},{"key":"10.1111\/jcpt.12089-BIB0002|jcpt12089-cit-0002","unstructured":"U.S. Food and Drug Administration Genomics http:\/\/www.fda.gov\/Drugs\/ScienceResearch\/ResearchAreas\/Pharmacogenetics\/default.htm"},{"key":"10.1111\/jcpt.12089-BIB0003|jcpt12089-cit-0003","unstructured":"U.S. Food and Drug Administration Table of Pharmacogenomic Biomarkers in Drug Labels http:\/\/www.fda.gov\/Drugs\/ScienceResearch\/ResearchAreas\/Pharmacogenetics\/ucm083378.htm"},{"key":"10.1111\/jcpt.12089-BIB0004|jcpt12089-cit-0004","unstructured":"European Medicines Agency Multidisciplinary: Pharmacogenomics http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/regulation\/general\/general_content_000411.jsp&mid=WC0b01ac058002958e&jsen-abled=true"},{"key":"10.1111\/jcpt.12089-BIB0005|jcpt12089-cit-0005","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1592\/phco.28.8.992","article-title":"Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use","volume":"28","author":"Frueh","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1111\/jcpt.12089-BIB0006|jcpt12089-cit-0006","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/sj.tpj.6500284","article-title":"Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs","volume":"4","author":"Zineh","year":"2004","journal-title":"Pharmacogenomics J"},{"key":"10.1111\/jcpt.12089-BIB0007|jcpt12089-cit-0007","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1345\/aph.1G464","article-title":"Discordance between availability of pharmacogenetics studies and pharmacogenetics-based prescribing information for the top 200 drugs","volume":"40","author":"Zineh","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1111\/jcpt.12089-BIB0008|jcpt12089-cit-0008","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1586\/17512433.1.4.505","article-title":"Current Japanese regulatory situations of pharmacogenomics in drug administration","volume":"1","author":"Ishiguro","year":"2008","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1111\/jcpt.12089-BIB0009|jcpt12089-cit-0009","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2133\/dmpk.DMPK-11-RV-082","article-title":"Similarities and differences between US and Japan as to pharmacogenomic biomarker information in drug labels","volume":"27","author":"Otsubo","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1111\/jcpt.12089-BIB0010|jcpt12089-cit-0010","unstructured":"Papaluca Amati M Personalised Medicine Towards the Market and Patients: The Approval Process 2011 http:\/\/ec.europa.eu\/research\/health\/pdf\/event06\/13052011\/marisa-papaluca-amati_en.pdf"},{"key":"10.1111\/jcpt.12089-BIB0011|jcpt12089-cit-0011","first-page":"6","article-title":"Comparing health care systems. Can the United States learn from other countries?","volume":"93","author":"Weaver","year":"2010","journal-title":"Minn Med"},{"key":"10.1111\/jcpt.12089-BIB0012|jcpt12089-cit-0012","unstructured":"U.S. Food and Drug Administration Drugs@FDA: FDA Approved Drug Products http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/"},{"key":"10.1111\/jcpt.12089-BIB0013|jcpt12089-cit-0013","unstructured":"National Library of Medicine Daily Med http:\/\/dailymed.nlm.nih.gov\/dailymed\/about.cfm"},{"key":"10.1111\/jcpt.12089-BIB0014|jcpt12089-cit-0014","unstructured":"Datapharm Communications Limited eMC http:\/\/www.medicines.org.uk\/emc\/"},{"key":"10.1111\/jcpt.12089-BIB0015|jcpt12089-cit-0015","unstructured":"Pharmaceutical Medical Device Agency Information of Ethical Drug Package Inserts http:\/\/www.info.pmda.go.jp\/psearch\/html\/menu_tenpu_base.html"},{"key":"10.1111\/jcpt.12089-BIB0016|jcpt12089-cit-0016","first-page":"3922","article-title":"Requirements on content and format of labeling for human prescription drug and biological products","volume":"71","author":"U. S. Department of Health and Human Services","year":"2006","journal-title":"Fed Reg"},{"key":"10.1111\/jcpt.12089-BIB0017|jcpt12089-cit-0017","unstructured":"European Commission A Guideline on Summary of Product Characteristics 2009 http:\/\/ec.europa.eu\/health\/files\/eudralex\/vol-2\/c\/smpc_guide-line_rev2_en.pdf"},{"key":"10.1111\/jcpt.12089-BIB0018|jcpt12089-cit-0018","unstructured":"Pharmaceutical Affairs Bureau, Ministry of Health & Welfare. Notification No. 606 (in Japanese)"},{"key":"10.1111\/jcpt.12089-BIB0019|jcpt12089-cit-0019","unstructured":"U.S. Food and Drug Administration Guidance for Industry: Labeling for Human Prescription Drug and Biological Products - Implementing the PLR Content and Format Requirements 2013 http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM075082.pdf"},{"key":"10.1111\/jcpt.12089-BIB0020|jcpt12089-cit-0020","unstructured":"Fukuhara H Period between world first launch and country launch 2006"},{"key":"10.1111\/jcpt.12089-BIB0021|jcpt12089-cit-0021","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2710.2009.01099.x","article-title":"Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations","volume":"35","author":"Tsuji","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"10.1111\/jcpt.12089-BIB0022|jcpt12089-cit-0022","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1001\/jama.1997.03540400055031","article-title":"Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening","volume":"277","author":"Ridker","year":"1997","journal-title":"JAMA"},{"key":"10.1111\/jcpt.12089-BIB0023|jcpt12089-cit-0023","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2133\/dmpk.18.48","article-title":"Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19","volume":"18","author":"Shimizu","year":"2003","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1111\/jcpt.12089-BIB0024|jcpt12089-cit-0024","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2710.2000.00281.x","article-title":"Pharmacogenetics and psychopharmacotherapy","volume":"25","author":"Poolsup","year":"2000","journal-title":"J Clin Pharm Ther"},{"key":"10.1111\/jcpt.12089-BIB0025|jcpt12089-cit-0025","unstructured":"European Medicines Agency Guideline on the Use of Pharmacogenetic Methodologies in the Pharmacokinetic Evaluation of Medicinal Products 2011 http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/02\/WC500121954.pdf"},{"key":"10.1111\/jcpt.12089-BIB0026|jcpt12089-cit-0026","unstructured":"U.S. Food and Drug Administration Guidance for Industry: Clinical Pharmacology Section of Labeling for Human Prescription Drug and Biological Products - Content and Format 2009 http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM109739.pdf"},{"key":"10.1111\/jcpt.12089-BIB0027|jcpt12089-cit-0027","unstructured":"U.S. Food and Drug Administration Guidance for Industry: Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products - Content and Format 2010 http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UC-M075066.pdf"},{"key":"10.1111\/jcpt.12089-BIB0028|jcpt12089-cit-0028","unstructured":"U.S. Food and Drug Administration FDA Drug Safety Communication: Reduced Effectiveness of Plavix (clopidogrel) in Patients Who are Poor Metabolizers of the Drug 2010 http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInform-ationforPatientsandProviders\/ucm203888.htm"},{"key":"10.1111\/jcpt.12089-BIB0029|jcpt12089-cit-0029","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2010.05.013","article-title":"ACCF\/AHA clopidogrel clinical alert: approaches to the FDA \u2018boxed warning\u2019: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons","volume":"56","author":"Holmes","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jcpt.12089-BIB0030|jcpt12089-cit-0030","doi-asserted-by":"crossref","first-page":"d4588","DOI":"10.1136\/bmj.d4588","article-title":"Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis","volume":"343","author":"Bauer","year":"2011","journal-title":"BMJ"},{"key":"10.1111\/jcpt.12089-BIB0031|jcpt12089-cit-0031","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10549-006-9428-0","article-title":"The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen","volume":"101","author":"Goetz","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1111\/jcpt.12089-BIB0032|jcpt12089-cit-0032","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1200\/JCO.2006.06.8072","article-title":"Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial","volume":"24","author":"Bonanni","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12089-BIB0033|jcpt12089-cit-0033","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10549-004-7751-x","article-title":"Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients","volume":"91","author":"Nowell","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1111\/jcpt.12089-BIB0034|jcpt12089-cit-0034","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1186\/bcr1640","article-title":"Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer","volume":"9","author":"Wegman","year":"2007","journal-title":"Breast Cancer Res"},{"key":"10.1111\/jcpt.12089-BIB0035|jcpt12089-cit-0035","doi-asserted-by":"crossref","first-page":"R284","DOI":"10.1186\/bcr993","article-title":"Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients","volume":"7","author":"Wegman","year":"2005","journal-title":"Breast Cancer Res"},{"key":"10.1111\/jcpt.12089-BIB0036|jcpt12089-cit-0036","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.2007.12.2705","article-title":"Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes","volume":"25","author":"Schroth","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12089-BIB0037|jcpt12089-cit-0037","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/j.1349-7006.2008.00780.x","article-title":"Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy","volume":"99","author":"Kiyotani","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1111\/jcpt.12089-BIB0038|jcpt12089-cit-0038","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1200\/JCO.2007.11.4850","article-title":"Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer","volume":"25","author":"Lim","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12089-BIB0039|jcpt12089-cit-0039","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1200\/JCO.2007.13.4957","article-title":"Germline pharmacogenetics of tamoxifen response: have we learned enough?","volume":"25","author":"Desta","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12089-BIB0040|jcpt12089-cit-0040","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/jnci\/djn127","article-title":"A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?","volume":"100","author":"Hayes","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/jcpt.12089-BIB0041|jcpt12089-cit-0041","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/clpt.2009.39","article-title":"Clinically available pharmacogenomics tests","volume":"86","author":"Flockhart","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12089-BIB0042|jcpt12089-cit-0042","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.clpt.2006.04.008","article-title":"Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants","volume":"80","author":"Schwarz","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12089-BIB0043|jcpt12089-cit-0043","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa0708078","article-title":"Genetic determinants of response to warfarin during initial anticoagulation","volume":"358","author":"Schwarz","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12089-BIB0044|jcpt12089-cit-0044","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/clpt.2011.185","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing","volume":"90","author":"Johnson","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12089-BIB0045|jcpt12089-cit-0045","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1592\/phco.28.9.1084","article-title":"Warfarin pharmacogenetics","volume":"28","author":"Limdi","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1111\/jcpt.12089-BIB0046|jcpt12089-cit-0046","first-page":"439","article-title":"Role of warfarin pharmacogenetic testing in clinical practice","volume":"11","author":"Tan","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1111\/jcpt.12089-BIB0047|jcpt12089-cit-0047","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1161\/CIRCULATIONAHA.111.070920","article-title":"A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II)","volume":"125","author":"Anderson","year":"2012","journal-title":"Circulation"},{"key":"10.1111\/jcpt.12089-BIB0048|jcpt12089-cit-0048","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/clpt.2011.186","article-title":"A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy","volume":"90","author":"Avery","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jcpt.12089-BIB0049|jcpt12089-cit-0049","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","article-title":"Estimation of the warfarin dose with clinical and pharmacogenetic data","volume":"360","author":"Klein","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12089-BIB0050|jcpt12089-cit-0050","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.healthpol.2009.09.006","article-title":"Personalized medicine: factors influencing reimbursement","volume":"94","author":"Meckley","year":"2010","journal-title":"Health Policy"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12089","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12089","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12089\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:05:02Z","timestamp":1671818702000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,29]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12089","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7,29]]}}}